Figure 2.

Neurocognitive performance over time in ketamine and midazolam treatment groups in a randomized controlled trial in treatment-resistant major depression. Figure depicts mean (±SD) T-scores in patients with treatment-resistant depression using a subset of cognitive domains derived from the MATRICS Consensus Cognitive Battery. Cognitive measurements were performed at baseline and 7 days following a single intravenous infusion of ketamine (0.5 mg/kg) or midazolam (0.045 mg/kg). *Indicates significant improvement in T-score over time regardless of treatment condition (p<0.05). There was no significant main effect of treatment and no significant treatment × time interaction.